The hunt for biomarkers for patients with hepatocellular carcinoma (HCC) or liver cancer ensues as an explosion of novel agents, either approved or in the clinical trials pipeline, opens the door for tremendous opportunity to develop heretofore not possible treatments...
Can-Fite Pharma announced the successful completion of an End-of-Phase 2 meeting with the U.S. FDA regarding its recently completed Phase II study of namodenoson in the treatment of hepatocellular cancer (HCC). The purpose of the meeting was to review the Phase II...
Michigan State University (MSU) College of Medicine investigator Bin Chen just was awarded $2.1 million by the National Institutes of Health (NIH) to scour vast databases of existing drugs in a quest to treat orphan diseases. The investigative team received an...
A research team from Shanghai’s Zhongshan Hospital joined by two Shanghai institutes under the Chinese Academy of Sciences have discovered that one-third of liver cancer samples features a mutation caused by aristolochic acids and connect this to the clinical use of...
Chinese researchers from Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai showed that neoadjuvant 3D conformal radiotherapy provided significantly better post-surgery survival outcomes than surgery alone in patients with resectable...
City of Hope reports that it is the first institution in the United States to open an immunotherapy clinical trial for liver cancer that, if successful, eventually represents a transformative treatment of the often fatal disease into an outpatient procedure. The...
